How have PBSV shares performed in 2024?

Pharma-Bio Serv's stock was trading at $1.05 on January 1st, 2024. Since then, PBSV stock has decreased by 28.6% and is now trading at $0.75. View the best growth stocks for 2024 here .

When is Pharma-Bio Serv's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our PBSV earnings forecast .

How were Pharma-Bio Serv's earnings last quarter?

Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) issued its quarterly earnings results on Monday, March, 18th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.03. The company earned $2.38 million during the quarter, compared to the consensus estimate of $5 million. Pharma-Bio Serv had a net margin of 4.05% and a trailing twelve-month return on equity of 3.95%.

How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv?

Pharma-Bio Serv announced a dividend on Thursday, December 21st. Investors of record on Tuesday, January 30th will be given a dividend of $0.075 per share on Thursday, February 15th. The ex-dividend date of this dividend is Monday, January 29th. Read our dividend analysis for PBSV .

What other stocks do shareholders of Pharma-Bio Serv own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE) , Allena Pharmaceuticals (ALNA) , AstroNova (ALOT) , Oracle (ORCL) , AT&T (T) , Yintech Investment (YIN) , Aeglea BioTherapeutics (AGLE) , Ampliphi Biosciences (APHB) , Carnival Co. & (CCL) and Earthstone Energy (ESTE) .

How do I buy shares of Pharma-Bio Serv?

Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:PBSV

Pharma-Bio Serv (PBSV) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free PBSV Stock Alerts

$0.75

-0.11 (-12.59%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.65
▼
$0.75
50-Day Range: $0.75
▼
$0.98
52-Week Range: $0.65
▼
$1.10

Volume: 14,159 shs
Average Volume: 6,111 shs
Market Capitalization: $17.22 million

P/E Ratio: 25.01
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Dividend Earnings Financials Headlines SEC Filings Short Interest

Get Pharma-Bio Serv alerts:

Ad Priority Gold

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

About Pharma-Bio Serv Stock (OTCMKTS:PBSV)

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.

PBSV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PBSV Stock News Headlines

April 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market Expectations

April 10, 2024 | americanbankingnews.com

Pharma-Bio Serv (OTCMKTS:PBSV) Stock Crosses Above 50 Day Moving Average of $0.89

April 17, 2024 | Wall Street Star (Ad)

This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

April 9, 2024 | tmcnet.com

Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com's Supplier Pre-assessment Program

April 3, 2024 | benzinga.com

Looking Into Biomarin Pharmaceutical's Recent Short Interest

March 19, 2024 | finance.yahoo.com

PBSV Releases Quarterly Results

March 19, 2024 | seekingalpha.com

Pharma-Bio Serv reports Q1 results

March 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for BridgeBio Pharma Amidst Strategic Bayer Collaboration and Promising Financial Outlook

April 17, 2024 | Wall Street Star (Ad)

This Apple-like Innovator is Revolutionizing Healthcare

March 4, 2024 | markets.businessinsider.com

Maintaining Hold on BridgeBio Pharma Amidst Bayer Partnership and Market Uncertainties

February 26, 2024 | marketwatch.com

BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update

February 23, 2024 | markets.businessinsider.com

Strong Voxzogo Performance Underpins Buy Rating for BioMarin Pharmaceutical

January 30, 2024 | finance.yahoo.com

PBSV Expands Margins and Markets

January 28, 2024 | msn.com

Jubilant Pharma Plans Stake Sale in Sofie Biosciences Amid Merger Deal

January 9, 2024 | markets.businessinsider.com

Optimistic Outlook: Buy Rating for BridgeBio Pharma with Promising Treatment Launches and Strategic Growth Drivers

January 8, 2024 | seekingalpha.com

BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner

January 3, 2024 | finance.yahoo.com

PBSV Reward Shareholders with High Yield

December 21, 2023 | finanznachrichten.de

Pharma-Bio Serv Inc.: Pharma-Bio Serv Announces Special Dividend

December 8, 2023 | msn.com

AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?

November 28, 2023 | markets.businessinsider.com

BioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In Germany

November 7, 2023 | markets.businessinsider.com

Promising Future for BridgeBio Pharma: Lebovitz’s Buy Rating Backed by Potential Blockbusters and Pipeline Assets

November 6, 2023 | markets.businessinsider.com

BridgeBio Pharma Receives Buy Rating Amid Promising Drug Pipeline Developments and Strong Financial Position

September 15, 2023 | finance.yahoo.com

PBSV Boosts Margins and Expands Markets

September 14, 2023 | finance.yahoo.com

Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2023

August 31, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN) and Phibro Animal Health (PAHC)

July 28, 2023 | thestreet.com

Pharma-Bio Serv Inc

July 17, 2023 | msn.com

BridgeBio Pharma: Positive ATTR-CM Treatment Data Leads To Other 2023 Catalysts

See More Headlines

Receive PBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/15 Dividend: 1/29/2024
Dividend Payable: 2/15/2024
Last Earnings: 3/18/2024
Today: 4/17/2024
Next Earnings (Estimated): 6/12/2024
Fiscal Year End: 10/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Business Services
Industry: Management consulting services
Sub-Industry: N/A
Current Symbol: OTCMKTS:PBSV
CUSIP: N/A
CIK: 1304161
Web: www.pharmabioserv.com
Phone: (787) 278-2709
Fax: 787-796-5168
Employees: 100
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.03
Trailing P/E Ratio: 28.61
Forward P/E Ratio: 10.73
P/E Growth: N/A
Net Income: $1.31 million
Net Margins: 4.05%
Pretax Margin: 5.65%
Return on Equity: 3.95%
Return on Assets: 3.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.10
Quick Ratio: 5.10

Sales & Book Value

Annual Sales: $16.98 million
Price / Sales: 1.16
Cash Flow: $0.07 per share
Price / Cash Flow: 13.11
Book Value: $0.70 per share
Price / Book: 1.23

Miscellaneous

Outstanding Shares: 22,960,000
Free Float: 20,207,000
Market Cap: $19.70 million
Optionable: Not Optionable
Beta: 0.51

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Victor Sanchez (Age 53)
CEO, President & President of European Operations
Comp: $323.67k
Mr. Pedro J. Lasanta (Age 64)
CFO, VP of Finance & Administration and Secretary
Comp: $225.6k
Ms. Elizabeth Plaza (Age 60)
Founder & Senior Strategic Consultant
Comp: $69.92k
Ms. Miriam Marrero M.B.A.
Human Resources Manager

Key Competitors

View All Competitors

PBSV Stock Analysis - Frequently Asked Questions

How have PBSV shares performed in 2024?: Pharma-Bio Serv's stock was trading at $1.05 on January 1st, 2024. Since then, PBSV stock has decreased by 28.6% and is now trading at $0.75.
View the best growth stocks for 2024 here.
When is Pharma-Bio Serv's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our PBSV earnings forecast.
How were Pharma-Bio Serv's earnings last quarter?: Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) issued its quarterly earnings results on Monday, March, 18th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.03. The company earned $2.38 million during the quarter, compared to the consensus estimate of $5 million. Pharma-Bio Serv had a net margin of 4.05% and a trailing twelve-month return on equity of 3.95%.
How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv?: Pharma-Bio Serv announced a dividend on Thursday, December 21st. Investors of record on Tuesday, January 30th will be given a dividend of $0.075 per share on Thursday, February 15th. The ex-dividend date of this dividend is Monday, January 29th.
Read our dividend analysis for PBSV.

What other stocks do shareholders of Pharma-Bio Serv own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), AstroNova (ALOT), Oracle (ORCL), AT&T (T), Yintech Investment (YIN), Aeglea BioTherapeutics (AGLE), Ampliphi Biosciences (APHB), Carnival Co. & (CCL) and Earthstone Energy (ESTE).
How do I buy shares of Pharma-Bio Serv?: Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PBSV) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial